Novo Nordisk said Hims & Hers has "failed to adhere to the law which prohibits mass sales of compounded drugs" under the "false guise" of personalization.
In this article
Novo Nordisk
on Monday said it is ending its collaboration with Hims & Hers
due to concerns about the telehealth company’s sales and promotion of cheaper knock-offs of the weight loss drug Wegovy.
Shares of Hims & Hers fell about 20% in premarket trading Monday.
Novo Nordisk said it's ending its collaboration due to concerns with Hims & Hers the company's sales and promotion of cheap…
Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe patents, and is…
Novo dropped its patent-infringement case against telehealth provider Hims & Hers after the companies agreed that Hims would sell…
Hims & Hers stock fall to a 12-month low after Novo said it's $49 Wegovy pill copy was "illegal"
Novo Nordisk, the maker of the weight loss drug Wegovy, is suing Hims & Hers for selling a cheaper version of the drug, the…
Novo Nordisk and Eli Lilly fell after Hims & Hers said it will offer a copy of the Wegovy pill for $49, far less than the $149…
